Boston, MA 06/18/2014 (wallstreetpr) – Novogen Limited (ADR) (NASDAQ:NVGN) and CanTx Inc., on June 17, 2014 announced that the proof-of-concept pre-clinical studies were successful. Novogen and its joint venture company CanTx Inc. also gave confirmation of the potency of Intra-Peritoneal Trx-1, their experimental drug.
The declaration was made on the basis of potency in animal models as well as its potential to prevent the recurrence of the cancer. This announcement is a part of ongoing the Drug Discovery and Therapy 2014 World Congress conference in Boston, which will be concluded on June 19, 2014. The group research was presented by Gil Mor, M.D. Ph.D., Professor of Obstetrics, Gynecology and Reproductive Science at Yale School of Medicine.
Intra-Peritoneal Trx-1
Intra-Peritoneal Trx-1 will be used in the primary ovarian cancer treatment, in case the cancer reaches the peritoneal cavity. Trx-1, the two companies said, can be used as the first-line therapy for the women-specific cancer. Intra-Peritoneal Trx-1 is basically developed for ovarian cancer treatment. It will focus mainly on the chemo-resistant ovarian cancer stem cells. Novogen Limited (ADR) (NASDAQ:NVGN) and CanTx, now have plans to file the Investigational New Drug application (IND) with USFDA by the start of 2015 as well as to begin Phase 1 study by 2015 mid.
Highlights Of The Presentation Of Data By Novogen And Cantx
The data which was presented on June 17, 2014 by these two companies show that Peritoneal Trx-1 can be used for significantly retarding the multiplication of highly chemo-resistant ovarian cancer stem cells in the animal model, which was highly representative of human situation only.
Statement From The CEO Of Novogen And Cantx
The CEO of Novogen Limited (ADR) (NASDAQ:NVGN) and CanTx, Graham Kelly, Ph.D., said that this was an outcome of the commercial collaboration between an academic institute and an industry. He added that the result has elevated the hopes for this ovarian cancer treatment- Trx-1 beyond the usual recovery of patients who reached the last stage of the disease. The treatment, he added, can be easily incorporated into first-line therapy along with the conventional chemotherapy.
